2. Baxter is currently undervalued, but is now on Goldman's "consensus buy" list with a one year target of $57. It's one of Goldman's top 15 holdings.
3. The IV Therapies market is coming back, and Baxter is (I think) regaining market share from CSL with a sharper pencil lately as well. (Lots of room to work a sharper pencil with a 53% margin.)
4. The Talecris buyout by Grifols is now working in Baxter's favor as they plan restructuring and consolidation.
5. The earnings and revenue numbers are projected to be much better in H2 now that the pump recall procedure and costs are accounted for.
6. The economy seems to be breaking out of the summer doldrums and picking up steam. There are trillions sitting on the sidelines in cash at the moment, and when that breaks loose from low interest instruments, watch the run back to the markets. The August employment figures may be a good sign of what's to come.